Transforming Antibody Discovery & Immunotherapy
At Abzyme Therapeutics, we’re pushing the boundaries of antibody engineering to solve some of the toughest challenges in oncology, neurology, and beyond.
- Conditionally Active Antibodies – pH-dependent anti-CD3 and other formats that reduce off-tumor toxicity while improving tumor targeting.
- Directed Evolution & Affinity Maturation – Rapid optimization of biologics for specificity, affinity, and tumor-microenvironment selectivity.
- Modular VHH Antibodies – Small, stable, and highly versatile camelid-derived antibodies for bispecifics, CAR-Ts, and antibody-drug conjugates.
- Broad Pipeline & Expertise – From immune checkpoint inhibitors (PD-1, TIGIT, HVEM) to novel therapeutics for solid tumors, AMD, and multiple sclerosis, our platforms are designed for speed, flexibility, and translational success.
With a proven record of NIH/DOD funding, multiple issued patents, and partnerships with pharma, biotech, and CROs, Abzyme offers fee-for-service projects, co-development, and licensing opportunities.
Whether you need advanced antibody discovery, optimization, or next-generation bispecific design, Abzyme is your partner in building conditionally active, best-in-class biologics.